Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,462.90 -6.40 (-0.12%) Dow
38,979.58 -132.58 (-0.34%) Nasdaq
17,736.25 +18.59 (+0.10%) Bitcoin USD
61,716.02 +399.75 (+0.65%) CMC Crypto 200
1,278.58 -5.21 (-0.41%)
ITCI Jan 2025 70.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:34PM EDT. Market open.
| Previous close | 10.66 |
| Open | 10.80 |
| Bid | 9.10 |
| Ask | 11.80 |
| Strike | 70.00 |
| Expiry date | 2025-01-17 |
| Day's range | 10.66 - 10.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 56 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.